# Royalty Pharma to present at the UBS Global Biopharma Conference

- Published: 2026-11-12
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/royalty-pharma-to-present-at-the-ubs-global-biopharma-conference/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

NEW YORK, Nov. 12, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference on Tuesday, November 17, 2026 at 5:40 a.m. ET / 10:40 a.m. GMT.

The webcast will be accessible from Royalty Pharma’s “Events” page at <a href="https://www.globenewswire.com/Tracker?data=ZHmTOteThzSx5kWJG0FI9FPuJDbJiZo2amP6zpzWmzFiLeZM4BRWOjbZ_HukrQQ7sp-posoV_x0aXrq7Qcbie23Lwb89yXQRSqFAiaG3gIrLRYhN8F21tlh2yeSz5Py7H8EhCx8tfDlLlX0IYAleB069ZX6bWjULna-WZz57wvA=" rel="nofollow">https://www.royaltypharma.com/investors/events/</a>. Webcasts will also be archived for a minimum of thirty days.

**About Royalty Pharma plc**

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=MF7GpD6yv8T4U1U90fYBRpea4DeAwCkZj2gvTdxala4eJC8e-51jOlpBs2WR7j5GQ6ihtOdG4Lec94kASxIRJe2Mx1wEl64VM9hkwJaeXbA=" rel="nofollow">www.royaltypharma.com</a>.

**Royalty Pharma Investor Relations and Communications**

+1 (212) 883-6772  
<a href="https://www.globenewswire.com/Tracker?data=Z1k-aU6JBVmxNxg1kMixw0ZOQ83la0i-Z6h40n2iwSHBp3872_L2sCetwjeVi9WqziZdaF_qm3YAmxVTjBBlxJYVRJbFr5Ui1ff5gQTkdBw=" rel="nofollow">ir@royaltypharma.com</a>

  
![](https://ml.globenewswire.com/media/NDMyZTE2NWYtMzc0NS00Nzk3LTk5ZDItMDI5YTQ0NDU4ZDA1LTUwMDEwNTI2NC0yMDI2LTExLTEyLWVu/tiny/Royalty-Pharma-plc.png)

## Related

- [BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results](https://healthcarenews.io/news/biocardia-reports-third-quarter-2026-business-highlights-and-financial-results.md)
- [Biomea Fusion to Participate in Upcoming Investor Conferences](https://healthcarenews.io/news/biomea-fusion-to-participate-in-upcoming-investor-conferences.md)
- [Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update](https://healthcarenews.io/news/azora-therapeutics-reports-2026-third-quarter-financial-results-and-provides-business-upda.md)
- [Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights](https://healthcarenews.io/news/journey-medical-corporation-reports-third-quarter-2026-financial-results-and-recent-corpor.md)